Genmab — December 2020
-
Shocking ORR
-
GEN will wipe the floor with Roche
-
N=12 only at optimal dose - still...
-
Rituximab still SOC...
-
Martin Hutchings var ikke til at tage fejl af - meget begejstret over epco. Flere årsager som sideeffects - sikkert grundet sc-version. Epco benytter ikke samme epitope på cd20 som af rituxan/gazyva, som tidligere er benyttet på patienterne. Imponerende og ikke tidligere set effekt.
-
Epco - interessant - AE’s forekommer på non-responders
-
Not so much on responders
-
KOL - epco safer than glofitamab
-
-
On par with glofitamab on efficacy
-
With risk-patient profiling epco can be used in out-patient setting
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind